4D-flow Cardiac MRI to Assess Pulmonary Arterial Pressure in Pulmonary Hypertension

Last updated: November 17, 2025
Sponsor: Centre Hospitalier Universitaire, Amiens
Overall Status: Completed

Phase

N/A

Condition

Pulmonary Arterial Hypertension

Williams Syndrome

Scleroderma

Treatment

4D-flow sequence

Clinical Study ID

NCT05103189
PI2020_843_0062
  • Ages > 18
  • All Genders

Study Summary

Due to radiation exposure and low but real risk of morbidity and mortality associated with right heart catheterization, non-invasive procedures to estimate mPAP are desired for the diagnosis of PH or to monitor treatment effectiveness. Echocardiography is used as a screening tool to estimate systolic pulmonary arterial pressure (sPAP), but due various limitations, this technique is not considered to be sufficiently accurate for the diagnosis of PH. The aim of 4D flow MRI is to evaluate the complete time-varying tridirectional velocity field in a volume of interest. It enables flow and velocity measurements in a vascular region of interest and visualization of vector plots of blood flow velocity fields. Previous studies have shown on the one hand, correlations between mPAP and hemodynamic parameters obtained by phase contrast MRI and, on the other hand, appearance of a vortical blood flow in the pulmonary artery in PH. More studies are required to confirm 4D MRI as a valuable tool for mPAP estimation in PH.

Following screening echocardiography, all patients will undergo right heart catheterization for PH assessment. Then, all patients will be referred for a complete cardiac MRI exam with the addition of a 4D Flow sequence (does not require supplementary injection of a contrast agent and does not extend the duration of the examination) followed promptly (within the same hour) by a Doppler-echocardiography. The data from each examination will be blindly interpreted from the results of the other one. No follow-up will be required for the study.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 18 years old,

  • Patient referred for cardiac MRI who previously underwent right heartcatheterization for pulmonary hypertension assessment,

  • Affiliation to a social security program,

  • Ability of the subject to understand and express opposition

Exclusion

Exclusion Criteria:

  • Age <18 years old,

  • Major obesity (> 140 kg) not allowing the patient to enter the tunnel of the machinewhose diameter is less than 70 cm,

  • Person under guardianship or curators,

  • Pregnant woman,

  • Allergy to gadolinium chelates,

  • Claustrophobia,

  • Any contraindications to MRI

Study Design

Total Participants: 28
Treatment Group(s): 1
Primary Treatment: 4D-flow sequence
Phase:
Study Start date:
October 21, 2021
Estimated Completion Date:
July 01, 2023

Connect with a study center

  • CHU Amiens-Picardie

    Amiens, 80000
    France

    Site Not Available

  • CHU Amiens-Picardie

    Amiens 3037854, 80000
    France

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.